Treatment patterns and outcomes of different subtypes of metastatic breast cancer patients in a Swedish real world setting with a focus on HER2-/HR+ subtype

被引：0
|
作者：
Lindman, H.
Szilcz, M.
Freilich, J.
Carlqvist, P.
Vertuani, S.
Anell, B.
Holm, B.
机构：
[1] Uppsala Univ, Uppsala, Sweden
[2] Novartis Oncol Nord, Taby, Sweden
[3] PAREXEL Int, Stockholm, Sweden
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-P1-16-10
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-16-10
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Treatment Patterns and Health Resource Utilization in Patients With HR+/ HER2- Locally Advanced or Metastatic Breast Cancer in Real-World Setting in Taiwan
    Novick, Diego
    Rajan, Narayan
    Wei, Alice
    Cheng, Rebecca
    Colman, Sam
    Szende, Agota
    VALUE IN HEALTH REGIONAL ISSUES, 2023, 36 : 98 - 104
  • [2] Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR + , HER2- metastatic breast cancer patients in Japan
    K. Nozawa
    M. Terada
    M. Onishi
    Y. Ozaki
    T. Takano
    W. Fakhouri
    D. Novick
    J. M. Haro
    L. H. Faris
    T. Kawaguchi
    Y. Tanizawa
    Junji Tsurutani
    Breast Cancer, 2023, 30 : 657 - 665
  • [3] Initial real world treatment patterns and outcomes of Abemaciclib for the treatment of HR+,HER2-metastatic breast cancer
    Carter, Gebra Cuyun
    Sheffield, Kristin M.
    Gossai, Anala
    Huang, Yu-Jing
    Zhu, Yajun Emily
    Bowman, Lee
    Smith, Emily Nash
    Mathur, Raina
    Cohen, Aaron B.
    Baxi, Shrujal
    Rybowski, Sarah
    Chong, Amy Lee
    Seidman, Andrew D.
    CANCER RESEARCH, 2020, 80 (04)
  • [4] Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR+, HER2-metastatic breast cancer
    Cuyun Carter, Gebra
    Sheffield, Kristin M.
    Gossai, Anala
    Huang, Yu-Jing
    Zhu, Yajun Emily
    Bowman, Lee
    Nash Smyth, Emily
    Mathur, Raina
    Cohen, Aaron B.
    Rasmussen, Erik
    Balakrishna, Shreya
    Morato Guimaraes, Claudia
    Rybowski, Sarah
    Seidman, Andrew D.
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (07) : 1179 - 1187
  • [5] Real-world Treatment Patterns and Outcomes in HR+/HER2+Metastatic Breast Cancer Patients: A National Cancer Database Analysis
    Statler, Abby B.
    Hobbs, Brian P.
    Wei, Wei
    Gupta, Annie
    Blake, Cassann N.
    Nahleh, Zeina A.
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [6] Real-world Treatment Patterns and Outcomes in HR+/HER2+ Metastatic Breast Cancer Patients: A National Cancer Database Analysis
    Abby B. Statler
    Brian P. Hobbs
    Wei Wei
    Annie Gupta
    Cassann N. Blake
    Zeina A. Nahleh
    Scientific Reports, 9
  • [7] Real world evidence study on treatment patterns and health resource utilization in patients with HR+/HER2- locally advanced or metastatic breast cancer in Korea
    Novick, Diego
    Lee, Sae Young
    Koo, Dong Hyun
    Szende, Agota
    Colman, Sam
    JOURNAL OF DRUG ASSESSMENT, 2022, 11 (01) : 12 - 19
  • [8] Abemaciclib for the treatment of HR+/HER2- breast cancer
    Exman, Pedro
    Tolaney, Sara M.
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2018, 3 (03): : 151 - 161
  • [9] Real-world effectiveness of palbociclib in HR+/HER2- metastatic breast cancer: a literature review
    Christiansen, Emilie Adrian
    Kuemler, Iben
    FUTURE SCIENCE OA, 2024, 10 (01):
  • [10] Sequencing Therapies: Optimal Treatment for HR+/HER2- Metastatic Breast Cancer
    Kaklamani, Virginia
    Rugo, Hope S.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2024, 22 (01) : 25 - 27
12345